Table 1

Incidence of molecular mutations in biliary tract cancer as determined by genomic sequencing10

MutationIntrahepatic cholangiocarcinoma (%)Extrahepatic cholangiocarcinoma (%)Gall bladder cancer (%)
ERBB2 amplification31116
BRAF substitution531
KRAS 15–2242–4711–19.2
PI3KCA substitution5714
FGFR1-3 fusion11–12.503
CDKN2A/B loss181719
IDH1/2 substitution15–233–40
ARID1A alteration11–201211–13
MET 400
BAP1 9–2504–13